ID   PC9 BIR
AC   CVCL_E4DL
SY   PC9BIR
RX   PubMed=39061985;
CC   Population: Chinese; Han and Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_232716; (20R)-10,15,20-trimethyl-2-[(4-methylpiperazin-1-yl)methyl]-18,19,20,21-tetrahydro-15H,17H-12,8-(metheno)pyrazolo[3',4':2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-7(6H)-one (BI-4020).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=39061985; DOI=10.3390/biomedicines12071412; PMCID=PMC11273927;
RA   Fukuda S., Suda K., Hamada A., Oiki H., Ohara S., Ito M., Soh J.,
RA   Mitsudomi T., Tsutani Y.;
RT   "Potential utility of a 4th-generation EGFR-TKI and exploration of
RT   resistance mechanisms -- an in vitro study.";
RL   Biomedicines 12:1412.1-1412.13(2024).
//